Norman David Eansor - 17 Nov 2025 Form 4 Insider Report for Marker Therapeutics, Inc. (MRKR)

Reporting relationship: Director
Issuer ticker: MRKR
Reported as of: 17 Nov 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Nov 2025, 16:10:21 UTC
Prior SEC filing: 14 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Julio C. Esquivel as Attorney-In-Fact for Norman David Eansor

Key filing fact

Norman David Eansor filed Form 4 for Marker Therapeutics, Inc. (MRKR) on 19 Nov 2025.

Key facts

This page summarizes Norman David Eansor's Form 4 filing for Marker Therapeutics, Inc. (MRKR).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 19 Nov 2025, 16:10.

Change

Previous filing in this sequence was filed on 14 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001270905 Primary reporting owner

Eansor Norman David

Relationship: Director
Address: C/O MARKER THERAPEUTICS, INC., 2450 HOLCOMBE BLVD, TMC PARTNERS OFFICE, HOUSTON
Signature: /s/ Julio C. Esquivel as Attorney-In-Fact for Norman David Eansor
Signature date: 19 Nov 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MRKR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +84,411
Change %
Price: $0.000000
Shares after: 84,411
Date: 17 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 84,411
Exercise price: $0.9548
Footnotes: F1

MRKR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +137,330
Change %
Price: $0.000000
Shares after: 137,330
Date: 17 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 137,330
Exercise price: $0.9548
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025.

Footnote F2

Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025.